662 results on '"Saul, Allan"'
Search Results
102. Comparison of Colorimetric Assays with Quantitative Amino Acid Analysis for Protein Quantification of Generalized Modules for Membrane Antigens (GMMA)
103. Modulation of Endotoxicity of Shigella Generalized Modules for Membrane Antigens (GMMA) by Genetic Lipid A Modifications
104. Invasive African Salmonella Typhimurium induces bactericidal antibodies against O-antigens
105. Stochastic Simulation of Endemic Salmonella enterica Serovar Typhi: The Importance of Long Lasting Immunity and the Carrier State
106. Epidemiology of Group B Streptococcus in developing countries
107. Corrigendum to “Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer” [Vaccine 30 (2012) 189–194]
108. Purification of antibodies to O antigen of Salmonella Typhimurium from human serum by affinity chromatography
109. Determination of protein concentration for protein–protein conjugates using ultraviolet absorption
110. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi
111. O:2-CRM197 Conjugates against Salmonella Paratyphi A
112. High Yield Production Process for Shigella Outer Membrane Particles
113. Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer
114. Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults
115. Evaluation of the Immunogenicity and Biological Activity of the Citrobacter freundii Vi-CRM 197 Conjugate as a Vaccine for Salmonella enterica Serovar Typhi
116. Vaccines for neglected diseases: challenges and opportunities
117. Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009
118. Studies on the binding of ligands to the beta-adrenergic receptor
119. Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines
120. Robust Noninferiority Tests for Potency of a Test Drug Against a Reference Drug
121. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
122. Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA)
123. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali
124. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure
125. Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
126. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
127. The Novartis Vaccines Institute for Global Health: a new initiative for developing vaccines for neglected diseases in developing countries
128. Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children
129. Year-to-Year Variation in the Age-Specific Incidence of Clinical Malaria in Two Potential Vaccine Testing Sites in Mali With Different Levels of Malaria Transmission Intensity
130. Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians
131. Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization
132. Mosquito stage, transmission blocking vaccines for malaria
133. Human Immunity and the Design of Multi-Component, Single Target Vaccines
134. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
135. Formulation of vaccines containing CpG oligonucleotides and alum
136. Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria
137. Malaria Vaccines Based on thePlasmodium falciparumMerozoite Surface Protein 3—Should We Avoid Amino Acid Sequence Polymorphisms or Embrace Them?
138. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42kDa merozoite surface protein 1 (MSP142) in the absence of an affinity tag
139. Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity
140. Potency assay design for adjuvanted recombinant proteins as malaria vaccines
141. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
142. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel®, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide
143. ASSESSMENT OF TRANSMISSION-BLOCKING ACTIVITY OF CANDIDATE Pvs25 VACCINE USING GAMETOCYTES FROM CHIMPANZEES
144. The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms
145. A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli
146. INDUCTION OF TRANSMISSION-BLOCKING IMMUNITY IN AOTUS MONKEYS BY VACCINATION WITH A PLASMODIUM VIVAX CLINICAL GRADE PVS25 RECOMBINANT PROTEIN
147. Posttranslational Modification of Recombinant Plasmodium falciparum Apical Membrane Antigen 1: Impact on Functional Immune Responses to a Malaria Vaccine Candidate
148. Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
149. Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
150. Improved yield of recombinant merozoite Surface protein 3 (MSP3) fromPichia pastoris using chemically defined media
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.